Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Most, But Not All, Canadians With Chronic Conditions Get Clinically Recommended Tests
Most Canadians with chronic conditions have a regular place of care, but there are some reported gaps in the management of their conditions according to a new study released today by the Canadian Institute for Health Information (CIHI). The study, Experiences With Primary Health Care in Canada, measures access to and quality of care from a patient perspective across Canada"s 10 provinces. The study is based on the responses of more than 11,000 people age 18 and older to Statistics Canada"s 2008 Canadian Survey of Experiences With Primary Health Care, which was jointly funded by CIHI and the Health Council of Canada.
generic viagra online
Government Plan Could Sacrifice Equality For Choice In The NHS, UK
In a letter to this week÷´s BMJ, a researcher expresses his concern on how in order to empower NHS patients with choice, the UK government is in danger of sacrificing the principle of equality on which the service was founded.
News of the day
Dental School 'Imprints' Students With Skills For Community Service
More than ever, pediatric dental students at the University of Maryland, Baltimore (UMB) are working in communities, with special emphasis on serving the underserved.
Oncology

Stellar Pharmaceuticals Inc. Announces Watson Pharma, Inc. Has Received A Conditional IDE Approval For Stellar's Uracyst(R) From The FDA

Stellar Pharmaceuticals Inc. ("Stellar" or the "Company") (OTCBB:SLXCF) is pleased to announce that its United States licensee, Watson Pharma, Inc. ("Watson") (NYSE:WPI), has received a conditional approval of their Investigational Device Exemption (IDE) to conduct clinical work with Uracyst® from The Food and Drug Administration (FDA) in the United States of America ("USA"). This will allow Watson to continue to move their Uracyst® development program forward towards the eventual approval for the sale of Uracyst® in USA. The conditional approval allows Watson to begin a blinded, placebo-controlled, pilot clinical trial in 100 subjects at 20 clinical study centers in the USA. Peter Riehl, Stellar"s President and CEO stated, "We are very pleased to see another important milestone completed by Watson as they continue to make progress towards the sale of Uracyst® in the largest pharmaceutical market in the world. Stellar is fortunate to have a partner as experienced as Watson is in the field of urology to develop the clinical program for the Uracyst marketing approval in the USA." Stellar


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009